Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Nanjing Nutrabuilding Bio-Tech Co. Ltd. manages 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. Each of these 7 actions is assigned to a different individual, as evidenced by the 7 distinct examiners listed. The portfolio spans 6 distinct art units, suggesting that the pending matters cover a variety of specialized topics within the biotechnology field. This distribution of 7 pending office actions across 7 distinct examiners means that no single examiner has influence over more than 1 case. The 6 distinct art units indicate a broad administrative footprint.
RAO, SAVITHA M is the busiest examiner for the company, holding 1 pending office action. This busiest examiner pending count of 1 is consistent across the entire portfolio of 7 pending office actions. Because there are 7 distinct examiners for 7 actions, the company must prepare for 7 unique sets of examiner expectations. The 6 distinct art units further suggest that these 7 pending office actions are being evaluated under several different technical guidelines. This lack of examiner and art unit concentration requires a highly diversified prosecution strategy to address the 7 distinct examiners involved. RAO, SAVITHA M is only 1 of the 7 individuals managing the company's workload.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| SHI, GENBIN | 1 | — | — |
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18422930 | L-ERGOTHIONEINE AND USES THEREOF | KIM, SEONG JONG | 22d |
| 17975028 | USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR ANTI-AGING | ISMAIL, REHANA | 33d |
| 18392229 | USE OF L-ERGOTHIONEINE FOR ALLEVIATING AND PREVENTING AGE-RELATED VISUAL DEGENERATION | SHI, GENBIN | 34d |
| 18785602 | Compositions and Methods for Preventing or Improving Premature Skin Aging | KWON, JOHN SEUNGJAI | — |
| 18626324 | Method and Composition for Mimicking Caloric Restriction by Administration of Ergothioneine | SEAMAN, D MARGARET M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17975028 | USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR ANTI-AGING | ISMAIL, REHANA | 33d |
| 18895434 | COMPOSITIONS AND METHODS FOR PROMOTING GLYCOGEN SYNTHASE ACTIVITY AND AUGMENTING GLYCOGEN STORAGE CAPABILITY | RAO, SAVITHA M | — |
| 18785602 | Compositions and Methods for Preventing or Improving Premature Skin Aging | KWON, JOHN SEUNGJAI | — |
| 18517037 | BETA-HYDROXYBUTYRATE WITH PURE BIOBASED CARBON CONTENT AND METHODS FOR PRODUCING THE SAME | HEASLEY, MEGHAN CHRISTINE | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1691 | 1 |
| 1615 | 1 |
| 1621 | 1 |
| 1628 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18895434 | COMPOSITIONS AND METHODS FOR PROMOTING GLYCOGEN SYNTHASE ACTIVITY AND AUGMENTING GLYCOGEN STORAGE CAPABILITY | RAO, SAVITHA M | 1691 | §102§103DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18785602 | Compositions and Methods for Preventing or Improving Premature Skin Aging | KWON, JOHN SEUNGJAI | 1615 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18626324 | Method and Composition for Mimicking Caloric Restriction by Administration of Ergothioneine | SEAMAN, D MARGARET M | 1625 | §101§102§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18422930 | L-ERGOTHIONEINE AND USES THEREOF | KIM, SEONG JONG | 1621 | §103 | Final Rejection | 22d | Pending | Jan 25, 2024 |
| 18392229 | USE OF L-ERGOTHIONEINE FOR ALLEVIATING AND PREVENTING AGE-RELATED VISUAL DEGENERATION | SHI, GENBIN | 1628 | §102§103§112 | Final Rejection | 34d | Pending | Dec 21, 2023 |
| 18517037 | BETA-HYDROXYBUTYRATE WITH PURE BIOBASED CARBON CONTENT AND METHODS FOR PRODUCING THE SAME | HEASLEY, MEGHAN CHRISTINE | 1626 | §103 | Final Rejection | — | Pending | Nov 22, 2023 |
| 17975028 | USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR ANTI-AGING | ISMAIL, REHANA | 1625 | §102§103 | Non-Final OA | 33d | Pending | Oct 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Nutrabuilding Bio-Tech Co. Ltd. has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Savitha M Rao has the most, with 1 of Nanjing Nutrabuilding Bio-Tech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
